Quinacrine Pellet Method of Nonsurgical Female Sterilization in Iran: Preliminary Report on a Clinical Trial

By Sheitaneh Soroodi-Moghaddam

For a study of the safety, efficacy and acceptability of female sterilization with quinacrine pellets in a private-practice setting, data on 160 women who obtained the procedure in Tehran between September 1990 and April 1994 were evaluated. Three-fourths of the women were monitored for at least one year, and more than half were monitored for more than two years. By the end of the study period, two women had become pregnant, for a gross pregnancy rate of 1.2%; neither pregnancy was ectopic. Within the first two months after the procedure, about half of the women reported complications or side effects, which were minor and easily treatable; after the first two months, the only side effect reported was delayed menses. The cost of sterilization with quinacrine pellets is one-tenth that of surgical sterilization. However, knowledge about the method is not widespread within the medical community in Iran.

(Author's note: Sheitaneh Soroodi-Moghaddam is a family planning specialist in private practice in Tehran, Iran.)

After the 1979 Islamic Revolution in Iran, the new government altered the 1967 fertility control policy, and the pace of population growth accelerated rapidly. In 1986, the population growth rate was 3.8% (3.4% when refugees from Afghanistan are excluded)—substantially higher than the 1976 rate of 2.7%, and one of the highest rates in the world. More recently, in response to social and economic pressures, the government has once again become very concerned with the issue of population growth. The Ministry of Health has taken various steps to promote family planning, from erecting billboards with messages discouraging the issue of population growth. The Ministry of Health has taken various steps to promote family planning, from erecting billboards with messages discouraging people from having large families, to providing free oral contraceptives.

Modern contraceptives are available in Iran and are used by roughly half of women in both urban and rural areas. Among urban women, 19% use the pill, 11% each have undergone voluntary sterilization and use the IUD, 8% rely on the condom and 2% are protected by their husband’s vasectomy; in rural areas, 27% use the pill, 11% have had a tubal occlusion, 4–5% use the IUD or condom and 1% have a husband who has had a vasectomy. Given the prevalence of tubal occlusion, the cost of hospitalization for sterilization and the risks associated with any surgical procedure, nonsurgical female sterilization is an alternative worth studying.

The only nonsurgical technique for tubal occlusion that is ready for clinical trials is the quinacrine pellet method, developed by Jaime Zipper and colleagues. The method involves the transcervical intruterine administration of quinacrine hydrochloride to nonpregnant women during the proliferative phase of the menstrual cycle (days 5–12).

This research note describes the first four years of an ongoing trial undertaken in a private-practice setting to determine whether this method is applicable in Iran. The goal of the study is to assess the safety, efficacy, acceptability and ease of delivery of quinacrine.

Study Population

Study participants were carefully selected from among women seeking voluntary sterilization at a single private clinic between September 1990 and April 1994; women were included only if they lived close enough to the clinic to be able to return for long-term follow-up. In all, 168 women underwent sterilization with quinacrine during this period; the analyses are based on the 160 women who returned to the clinic for all scheduled follow-up visits through August 1994. Thus, all of the women were monitored for at least four months; three-fourths were monitored for one year or more, and slightly more than half for more than two years.

Participants were almost evenly divided between those aged 26–35 and those aged 36–45 (52% and 47%, respectively). Two younger women also underwent the procedure: a 19-year-old for whom another pregnancy was medically contraindicated and a 21-year-old who had six children. The women had between one and 11 children: Some 24% had 1–3 children, 56% had 4–6, 18% had 7–9 and 3% had 10 or 11.

Procedure and Results

To ensure informed consent, all prospective acceptors and their husbands were counseled by a family planning specialist prior to the procedure. Counseling included a detailed description of the method and its administration, possible complications and side effects, and the risk of failure. The counselor explained that the effect of the procedure is intended to be permanent and not reversible. Both the wife and the husband signed an informed-consent form.

The International Federation for Family Health quinacrine study protocol, based on the work of Zipper and his colleagues, was applied throughout the study. Originally, Zipper recommended that quinacrine be administered in three doses of 252 mg (seven pellets of 36 mg each) at one-month intervals; this regimen was used for the first 62 procedures. At that point in the study, however, the provider learned that Zipper had changed his recommendation to two monthly doses, each consisting of 252 mg of...
quinaldrine plus 50 mg of an antiprosta
glandin to lessen spasm and thereby re-
duce the failure rate and the incidence of
minor side effects. These changes were
adopted for the last 98 procedures. (Ibu-
profen was available only in pellets of 18.5
mg, so the actual dose of antiprosta-
glandin used was 55.5 mg, administered in
three pellets.)

A modified Copper T IUD inserter was
used to administer the quinacrine, ac-
cording to the following procedure: After
preparing the cervix and sounding the
uterus, the clinician set the blue depth
marker on the inserter sleeve, removed the
plastic cap and advanced the inserter to the
fundus. She then withdrew the inserter
0.5 cm, fixed the inserter sleeve and slow-
ly advanced the plunger to expel all pellets
at the fundus. The inserter was then with-
drawn. After each insertion, the woman
was given a five-day course of antibiotics.

Women returned to the facility for fol-
low-up one, two and 15 days after each in-
sertion; one, two, three and six months
after the last insertion; and then annual-
ly for three years. There was no charge for
these visits. A cycle of oral contraceptives
was provided at the time of the last in-
sertion and at the one- and two-month fol-
low-up visits.

By the end of the study period, two
women had become pregnant (one who
had undergone the three-dose method
and one who had had two doses), for a
gross pregnancy rate of 1.2%; neither preg-
nancy was ectopic. Approximately half of
the women experienced complications or
side effects within the first two months
after the procedure (see Table 1). Only two
women complained of multiple compli-
cations (two each). All complications and
side effects were of a minor nature—pre-
dominantly lower abdominal pain, local
itching and fever—and were easily reme-
died. No complications were reported
after the two-month follow-up visit except
for delayed menses.

Discussion

In several respects, sterilization with
quinacrine appears to be superior to other
contraceptive methods available in Iran.
The failure rate of 1.2% observed in this
study is quite acceptable. Furthermore, the
complications and side effects reported by
the study participants were minor when
compared with those associated with sur-
gical sterilization. The method also proved
to be very easy to deliver in a private-prac-
tice setting, and its cost was only one-tenth
that of surgical sterilization. Although the
study did not measure women’s satisfac-
tion with the method, it appears to be very
high in some instances. For example, on
the advice of one study participant, 18 of
her extended family members obtained
quinacrine sterilization.

Despite the potential advantages of
quinacrine sterilization, the method is not
widely known in the medical communi-
ty. Anecdotal evidence suggests that as a
result, some Iranian women have been
dissuaded by their family doctors from
undergoing the procedure, even though
it would have been appropriate to the
woman’s needs.

Similarly, women who have undergone
the procedure have subsequently en-
countered physicians whose lack of
knowledge about it became an obstacle to
appropriate care. For example, one wom-
an visited a doctor several months after
undergoing sterilization with quinacrine
to obtain confirmation of its effectiveness.
The doctor told her that a few pellets could
not possibly make one infertile, but he re-
ferred her to a radiologist for a hystero-
salpingography. The test, which involves
x-raying the uterus and fallopian tubes
after injecting a dye, showed that both
tubes were indeed occluded—a result that
surprised both the radiologist and the doc-
tor who made the referral. However, this
test was a poor choice because the pres-
sure it creates in the tubes could have dis-
lodged the plug of scar tissue and re-
opened a tube; fortunately, this did not
happen in this instance.

In another case, a woman who had ob-
tained a nonsurgical sterilization and per-
ineoplasty went to another obstetrician-
gynecologist about a year later because she
had a slight discharge. When the doctor
asked her what method of birth control she
was using, she replied that she had un-
dergone tubal occlusion using pellets.
Dismissing this answer, the doctor insisted
that the woman had likely been the victim of
a scam and that her previous physician had
probably inserted a contraceptive implant
without her knowledge. Only when the
doctor examined the woman and com-
mented on how well the perineoplasty had
been done did he believe the woman’s ac-
count.

Thus, dissemination of information
about tubal occlusion with quinacrine pel-
lets is critical for the proper introduction
and steady proliferation of this simple,
low-cost method.

References

1. A. Aghajanian, “Population Change in Iran, 1966–86: A Stalled Demographic Transition?” Population and De-

2. United Nations Population Fund, Family Planning in
Islamic Republic of Iran, Tehran, 1994.

3. J. Zipper et al., “Efficacy of Two Insertions of 100-
Minute Releasing Quinacrine Hydrochloride Pellets for
Non-Surgical Female Sterilization,” Advances in Contra-

4. International Federation for Family Health (IFFH),
“Protocol for Straight and Comparative Studies of Non-
surgical Female Sterilization by Quinacrine Pellets and
Quinacrine Pellets Plus Adjuvants,” Leasburg, N.C.,
USA, 1992.

5. J. Zipper et al., “Quinacrine Hydrochloride Pellets:
Preliminary Data on a Nonsurgical Method of Female
Sterilization,” International Journal of Gynaecology and

6. E. Kessel, IFFH, personal communication, 1992; and
J. Zipper, M. Rivera and A. Dabancens, “Stérisilation
Feminine Non-Chirurgicale: Utilisation de Pellets Endo-
Utérins de Quinacrine et Betamethasone. Révision du Sujet:
Bases Expérimetales-Pharmacologie-Toxicologie-
Efficacité” (Non-Surgical Female Sterilization: Use of
Endo-Uterine Pellets of Quinacrine and Betamethasone.
Review of Question: Experimental Basis, Pharmacolo-
gy, Toxicology, Efficacy). Revue Française de Gynécologie et

Resumen

En un estudio sobre la seguridad, eficacia y
aceptabilidad de la esterilización femenina en
base a grageas de quinacrina en un medio de
consulta médica privada, se evaluaron los datos
de 160 mujeres que se sometieron a este pro-
cedimiento en Teherán, entre septiembre de
1990 y abril de 1994. Se controló al 75% de las
mujeres por un periodo mínimo de un año, y
más de la mitad por más de dos años. Al final
de este estudio, dos mujeres quedaron embaraza-
das, lo cual significó una tasa bruta de emba-
razos del 1.2%; ninguno de los embarazos fue
ectópico. Dentro de los primeros dos meses de
realizado el procedimiento, aproximadamen-
te la mitad de las mujeres registraron compli-
caciones o efectos secundarios, los cuales fue-
ron pequeños y de fácil tratamiento; luego de
los dos primeros meses, el único efecto secun-
dario fue el retraso de la menstruación. La
esterilización en base a grageas de quinacrina
cuesta la décima parte del valor de una esteri-
lización quirúrgica. Sin embargo, no se ha di-
(continued on page 127)
Quinacrine Pellet Method... (continued from page 123) seminado ampliamente el conocimiento de este método entre la comunidad médica de Irán.

Résumé
Aux fins d’une étude sur la sécurité, l’efficacité et l’acceptabilité de la stérilisation féminine par pastilles de quinacrine en pratique de clientèle, les données relatives à 160 femmes ayant obtenu la procédure à Téhéran entre les mois de septembre 1990 et d’avril 1994 ont été évaluées. Soixante-quinze pour cent des femmes ont été surveillées pendant au moins un an, et plus de la moitié, pendant plus de deux ans. Au terme de la période d’étude, deux femmes s’étaient retrouvées enceintes, soit un taux de grossesse brut de 1,2%; aucune de ces deux grossesses ne s’était avérée extra-utérine. Au cours des deux premiers mois qui avaient suivi la procédure, la moitié des femmes environ s’étaient plaintes de complications ou d’effets secondaires, toutefois mineurs et faciles à traiter. Au terme des deux premiers mois, le seul effet secondaire signalé était celui de règles tardives. Le coût de la stérilisation par pastilles de quinacrine est 10 fois inférieur à celui de la procédure chirurgicale. La méthode est cependant peu connue dans les milieux médicaux iraniens.